SCHEMBL2577652

SCHEMBL2577652

C=C(OC)C(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18612967 0.73
SCHEMBL1721841 0.71
SCHEMBL1334304 0.71
SCHEMBL15750890 0.71
SCHEMBL28909 0.71
SCHEMBL8068886 0.71
SCHEMBL5610835 0.71
SCHEMBL28876554 0.71
SCHEMBL1705442 0.69
SCHEMBL4215190 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation GILEAD PHARMASSET LLC (US) 2018-10-16 US disclosed
WO-2016057500-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-14 WO disclosed
US-9216960-B2 Spiro[2.4]heptanes for treatment of Flaviviridae infections UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2015-12-22 US disclosed
US-20150079036-A1 Spiro[2.4]heptanes for Treatment of Flaviviridae Infections UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2015-03-19 US disclosed
US-8946242-B2 Spiro[2.4]heptanes for treatment of flaviviridae infections UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2015-02-03 US disclosed
US-8921384-B2 Spiro[2.4]heptanes for treatment of flaviviridae infections UNVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2014-12-30 US disclosed
EP-2814816-A2 SPIRO [2.4]HEPTANES FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS University Of Georgia Research Foundation, Inc. (US) 2014-12-24 EP disclosed
US-20140140958-A1 Spiro[2.4]heptanes for Treatment of Flaviviridae Infections UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2014-05-22 US disclosed
US-20140140957-A1 Spiro[2.4]heptanes for Treatment of Flaviviridae Infections UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2014-05-22 US disclosed
US-8673926-B2 Spiro[2.4]heptanes for treatment of flaviviridae infections UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2014-03-18 US disclosed
US-20130224152-A1 Spiro[2.4]heptanes for Treatment of Flaviviridae Infections UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2013-08-29 US disclosed
WO-2013123138-A2 SPIRO [2.4]HEPTANES FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2013-08-22 WO disclosed
EP-1670787-B1 CYTOKINE INHIBITORS ITHERX PHARMA INC (US) 2012-05-30 EP disclosed
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PHARMASSET, INC. 2011-11-03 US disclosed
EP-2251015-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation Pharmasset, Inc. (US) 2010-11-17 EP disclosed
US-20090306095-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2009-12-10 US disclosed
EP-1411954-A2 MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION Pharmasset Limited (BB) 2004-04-28 EP disclosed
US-20030087873-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation PHARMASSET, INC. 2003-05-08 US disclosed
WO-2002032920-A2 MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION PHARMASSET LIMITED (BB) 2002-04-25 WO disclosed
US-4415572-A CARDIOTONIC AND INOTROPIC AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1983-11-15 US disclosed